
Claims

1. A controlled-release C-type natriuretic peptide ("CNP") agonist, wherein said controlled-release CNP agonist comprises a CNP moiety of SEQ ID NO:24, the controlled-release CNP agonist being ~~is~~ a compound of formula (IIf):




(IIf) or a pharmaceutically acceptable salt thereof;

wherein

the unmarked dashed line indicates the attachment to a nitrogen provided by the side chain of the lysine at position 26 of ~~a~~ the CNP moiety of SEQ ID NO:24 by forming an amide bond, wherein within SEQ ID NO:24 the cysteines at positions 22 and 38 are connected through a disulfide-bridge; and


the dashed line marked with the asterisk indicates the attachment to -Z having the structure



,

wherein

each -Z^a is




wherein

each c1 is an integer independently ranging from 200 to 250.

2. The controlled-release CNP agonist of claim 1, wherein each c1 is about 225.

3. The controlled-release CNP agonist of claim 1, wherein the controlled-release CNP agonist comprises a CNP moiety of SEQ ID NO:24, the controlled-release CNP agonist beingis a compound of formula (IIf ’):




(IIf ’) or a pharmaceutically acceptable salt thereof;

wherein

the unmarked dashed line indicates the attachment to a nitrogen provided by the side chain of the lysine at position 26 of the CNP moiety of SEQ ID NO:24 by forming an amide bond, wherein within SEQ ID NO:24 the cysteines at positions 22 and 38 are connected through a disulfide-bridge; and


the dashed line marked with the asterisk indicates the attachment to -Z having the structure



,

wherein


each -Z^a is



wherein

each c1 is an integer independently ranging from 200 to 250.

4. The controlled-release CNP agonist of claim 1 ~~or 2~~, wherein the controlled-release CNP agonist comprises a CNP moiety of SEQ ID NO:24, the controlled-release CNP agonist being ~~is~~ a compound of formula (IIf '):




(IIf ') or a pharmaceutically acceptable salt thereof;

wherein

the unmarked dashed line indicates the attachment to a nitrogen provided by the side chain of the lysine at position 26 of the CNP moiety of SEQ ID NO:24 by forming an amide bond, wherein within SEQ ID NO:24 the cysteines at positions 22 and 38 are connected through a disulfide-bridge; and


the dashed line marked with the asterisk indicates the attachment to -Z having the structure



,

wherein

each -Z^a is



wherein

each c1 is an integer independently ranging from 200 to 250.

5. The controlled-release CNP agonist of claim 3 or 4, wherein each c1 is about 225.

6. A pharmaceutical composition comprising the controlled-release CNP agonist of any one of claims 1 to 5 and at least one excipient.

7. The controlled-release CNP agonist of any one of claims 1 to 5 or the pharmaceutical composition of claim 6 for use as a medicament.

8. The controlled-release CNP agonist or the pharmaceutical composition for use as a medicament of claim 7, wherein the medicament is to be used in the treatment of achondroplasia.

9. Use of the controlled-release CNP agonist of any one of claims 1 to 5 or the pharmaceutical composition of claim 6 for the manufacture of a medicament for treating achondroplasia.